Sanofi

The U.S. Food and Drug Administration has greenlighted Sanofi’s (SNY) type 1 diabetes therapy Tzield for expanded use in stage 3 of the disease under its accele...

Sanofi ( (SNY) ) has issued an announcement. In June 2026, Sanofi detailed Action 2026, its twelfth annual global employee stock purchase plan, underscoring a...

Sanofi (SNYNF) announced an update on their ongoing clinical study. Sanofi Tracks Real-World Safety Awareness for ARAVA in Saudi Arabia The study, titled “Pos...

Sanofi (SNYNF) announced an update on their ongoing clinical study. Sanofi has terminated a Phase 2 trial that tested amlitelimab as a stand‑alone treatment fo...

Technology Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit Licensing Sanofi (SNY) scrapped a final-phase study Wednesday of a...

After Sanofi (SNY) announced that it is stopping the pivotal MOBILIZE study evaluating riliprubart in chronic inflammatory demyelinating polyneuropathy patients...

Sanofi SNY announced that it is discontinuing the phase III MOBILIZE study, which is evaluating its investigational drug, riliprubart, in patients with chronic...

Stocks are under pressure this morning as investors confront escalating U.S.-Iran tensions and a highly anticipated inflation report. Futures are pointing lower...

Stifel notes that Sanofi (SNY) announced this morning that they are discontinuing the MOBILIZE Phase 3 study of riliprubart in CIDP patients refractory to IVIg...